Cargando…

2696. Breakthrough Toxoplasmosis While on Atovaquone Prophylaxis Following Allogeneic Hematologic Stem Cell Transplantation

BACKGROUND: The opportunistic parasite Toxoplasma causes life-threatening complications in immunocompromised hosts such as hematopoietic cell transplantation (HCT) recipients. Trimethoprim-sulfamethoxazole (TMP-SMX) is the agent of choice in preventing Pneumocystis jirovecii pneumonia and Toxoplasma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chueng, Teresa A, Raja, Mohammed A, Morris, Michele I, Komanduri, Krishna V, Camargo, Jose F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810317/ http://dx.doi.org/10.1093/ofid/ofz360.2373

Ejemplares similares

Atovaquone ameliorate gastrointestinal Toxoplasmosis complications in a pregnancy model
por: Oz, Helieh S., et al.
Publicado: (2012)

Toxoplasmosis complications and novel therapeutic synergism combination of diclazuril plus atovaquone
por: Oz, Helieh S.
Publicado: (2014)

2660. Infection Complications Following Mismatched Allogeneic Hematopoietic Cell Transplantation
por: Ebisu, Yosuke, et al.
Publicado: (2019)

Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
por: Bakshi, Rahul P., et al.
Publicado: (2018)

Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis
por: Kang, Seung Hun, et al.
Publicado: (2015)

1024. Evaluation of Atovaquone Prescribing for Pneumocystis jiroveci Pneumonia (PJP) Prophylaxis
por: Aleissa, Muneerah, et al.
Publicado: (2019)

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
por: Tommasi, Chiara, et al.
Publicado: (2011)

2709. Breakthrough fungal infection after isavuconazole primary prophylaxis in patients with hematologic malignancy and hematopoietic stem cell transplant: Systematic Review
por: Ishida, Keiko, et al.
Publicado: (2023)

Delayed Onset of Symptoms and Atovaquone-Proguanil Chemoprophylaxis Breakthrough by Plasmodium malariae in the Absence of Mutation at Codon 268 of pmcytb
por: Teo, Beatrix Huei-Yi, et al.
Publicado: (2015)

Discordance Between Radiologic Findings and Molecular Testing in Patients With Underlying Hematologic Malignancy and Coronavirus Disease 2019
por: Raja, Mohammed, et al.
Publicado: (2020)

Assessment of acceptability and ease of use of atovaquone/proguanil medication in subjects undergoing malaria prophylaxis
por: Nicosia, V, et al.
Publicado: (2008)

2696. Impact of an Ultrasensitive Cytomegalovirus (CMV) Quantitative Nucleic Acid Test (qNAT) on CMV Detection and Therapy in Renal Transplant Recipients
por: Beechar, Vivek, et al.
Publicado: (2023)

Breakthrough Bacteremia with Meropenem-resistant Pseudomonas aeruginosa in Hematologic Malignancy Patients Receiving Levofloxacin Prophylaxis
por: Hakki, Morgan, et al.
Publicado: (2017)

415. Breakthrough Invasive Fungal Infections in Adult Hematologic Malignancy Patients Receiving Isavuconazole Prophylaxis
por: DeVoe, Catherine, et al.
Publicado: (2018)

Babesia microti Variant With Multiple Resistance Mutations Detected in an Immunocompromised Patient Receiving Atovaquone Prophylaxis
por: Holbrook, Nolan R, et al.
Publicado: (2023)

Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation
por: Liberatore, Carmine, et al.
Publicado: (2021)

Breakthrough viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients receiving levofloxacin prophylaxis in a Japanese hospital
por: Kimura, Muneyoshi, et al.
Publicado: (2016)

Antimalarial pharmacology and therapeutics of atovaquone
por: Nixon, Gemma L., et al.
Publicado: (2013)

Late-Onset Cerebral Toxoplasmosis After Allogeneic Hematopoietic Stem Cell Transplantation
por: Khalaf, Ahmed M., et al.
Publicado: (2017)

Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol)
por: Malagola, Michele, et al.
Publicado: (2022)

360. Breakthrough Invasive Pulmonary Aspergillosis During Isavuconazole Prophylaxis in Patients with Hematologic Malignancies: A Single-Center Experience
por: Fontana, Lauren, et al.
Publicado: (2018)

Cerebral toxoplasmosis after allogeneic hematopoietic stem cell transplantation diagnosed by megagenomic analysis
por: Shen, Kai, et al.
Publicado: (2019)

Atovaquone/proguanil‐induced autoimmune‐like hepatitis
por: Terziroli Beretta‐Piccoli, Benedetta, et al.
Publicado: (2017)

Reversible Cerebral Vasoconstriction Syndrome due to Atovaquone
por: Makino, Takahiro, et al.
Publicado: (2017)

Breakthrough Covid‐19 infections in vaccinated recipients of allogeneic stem cell transplantation
por: Fourati, Slim, et al.
Publicado: (2022)

Anti-Thymocyte Globulin Prophylaxis in Patients With Hematological Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: An Updated Meta-Analysis
por: Yang, Xue, et al.
Publicado: (2021)

The promise of CD4(+)FoxP3(+) regulatory T-cell manipulation in vivo: applications for allogeneic hematopoietic stem cell transplantation
por: Copsel, Sabrina, et al.
Publicado: (2019)

2120. Respiratory Viral Infections in Patients with Hematologic Malignancies
por: Cardenas, Jorge Luis, et al.
Publicado: (2022)

Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting
por: Marzolini, Maria A. V., et al.
Publicado: (2021)

Plasmodium falciparum Malaria and Atovaquone-Proguanil Treatment Failure
por: Durand, Rémy, et al.
Publicado: (2008)

Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria
por: Blanshard, Andrew, et al.
Publicado: (2021)

Atovaquone: An Inhibitor of Oxidative Phosphorylation as Studied in Gynecologic Cancers
por: Kapur, Arvinder, et al.
Publicado: (2022)

Tolerability of Atovaquone—Proguanil Application in Common Buzzard Nestlings
por: Wiegmann, Anja, et al.
Publicado: (2022)

Diagnostic significance of C-reactive protein and hematological parameters in acute toxoplasmosis
por: Sandri, Vanessa, et al.
Publicado: (2020)

Risk of recurrent stroke and antiplatelet choice in breakthrough stroke while on aspirin
por: Kim, Joon-Tae, et al.
Publicado: (2020)

Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis
por: Staines, Henry M, et al.
Publicado: (2018)

1139. Novel Formulation SUBA-Itraconazole Prophylaxis in Patients With Hematological Malignancy or Undergoing Allogeneic Stem Cell Transplantation: Follow-up Survival Data
por: Lindsay, Julian, et al.
Publicado: (2018)

Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan
por: Haraguchi, Mizuki, et al.
Publicado: (2023)

CAR T-Cell Therapy: On the Verge of Breakthrough in Many Hematologic Malignancies
por: Stadtmauer, Edward, et al.
Publicado: (2017)

Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies
por: Chien, Kelly S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i8epjkm2op5pdfv18sc00h2btu